A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-05-06 DOI:10.1080/14796694.2025.2488226

Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina, Timothy Panella, Tibor Csőszi, Paola Gerletti, Mahgull Thakur, Anna Poll, Alessandra di Pietro, Dirk Schadendorf

引用次数: 0

查看原文本刊更多论文

STARBOARD研究中encorafenib联合binimetinib和pembrolizumab治疗BRAF v600突变黑色素瘤的初步结果的简单语言总结。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.